Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Drug Profile

Eftrenonacog alfa - Bioverativ/Swedish Orphan Biovitrum

Alternative Names: Alprolix; BIIB-029; Coagulation factor IX recombinant immunoglubulin G1 fusion protein; Eftrenonacog alfa; Factor IX-Fc; FIX-Fc; Recombinant factor IX Fc; rFIXFc

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Biogen; Bioverativ; Swedish Orphan Biovitrum
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 28 Feb 2018 Launched for Haemophilia B (In adolescents, In children, In infants, In neonates, In adults) in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top